Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBVNYSE:JNJ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$183.31+0.8%$189.64$153.58▼$218.66$323.54B0.566.25 million shs2.70 million shsJNJJohnson & Johnson$153.28+0.1%$155.67$140.68▼$169.99$368.56B0.427.96 million shs3.40 million shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie-1.63%+2.50%+6.90%-9.57%+11.53%JNJJohnson & Johnson-0.27%+4.63%-2.44%-4.04%+1.27%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABBVAbbVie4.817 of 5 stars3.43.04.23.93.32.51.3JNJJohnson & Johnson4.9524 of 5 stars3.35.04.23.93.42.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.82Moderate Buy$210.9515.08% UpsideJNJJohnson & Johnson 2.55Moderate Buy$170.8811.49% UpsideCurrent Analyst Ratings BreakdownLatest JNJ and ABBV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025ABBVAbbVieCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$210.00 ➝ $205.005/13/2025JNJJohnson & JohnsonLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/13/2025JNJJohnson & JohnsonLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$169.00 ➝ $153.005/8/2025ABBVAbbVieBNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold4/29/2025ABBVAbbVieGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$214.00 ➝ $216.004/28/2025ABBVAbbVieEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$204.00 ➝ $205.004/28/2025ABBVAbbVieMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$241.00 ➝ $250.004/24/2025JNJJohnson & JohnsonBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/22/2025ABBVAbbVieCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$210.004/17/2025ABBVAbbVieGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$214.00 ➝ $214.004/17/2025JNJJohnson & JohnsonBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$166.00 ➝ $165.00(Data available from 5/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$57.37B5.64$13.55 per share13.53$1.90 per share96.48JNJJohnson & Johnson$89.33B4.13$12.59 per share12.17$29.69 per share5.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.28B$2.3576.3213.111.627.59%296.28%12.65%7/24/2025 (Estimated)JNJJohnson & Johnson$14.07B$8.9923.0313.852.5618.20%34.24%13.63%7/16/2025 (Estimated)Latest JNJ and ABBV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/25/2025Q1 2025ABBVAbbVie$2.40$2.46+$0.06$0.72$12.91 billion$13.34 billion4/15/2025Q1 2025JNJJohnson & Johnson$2.59$2.77+$0.18$4.54$21.65 billion$21.89 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.563.58%+6.04%279.15%53 YearsJNJJohnson & Johnson$5.203.39%+5.43%57.84%64 YearsLatest JNJ and ABBV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/15/2025JNJJohnson & Johnsonquarterly$1.303.37%5/27/20255/27/20256/10/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVie17.940.660.55JNJJohnson & Johnson0.431.110.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%JNJJohnson & Johnson69.55%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.25%JNJJohnson & Johnson0.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie50,0001.77 billion1.76 billionOptionableJNJJohnson & Johnson152,7002.41 billion2.40 billionOptionableJNJ and ABBV HeadlinesRecent News About These CompaniesJohnson & Johnson (NYSE:JNJ) Trading Up 0.3% - Should You Buy?May 22 at 1:25 PM | marketbeat.com3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any MarketMay 22 at 11:00 AM | marketbeat.comJNJ Down 6% in 3 Months: How to Play the Stock Amid Various ChallengesMay 22 at 10:11 AM | zacks.comJohnson & Johnson (NYSE:JNJ) Shares Sold by Novak & Powell Financial Services Inc.May 22 at 8:10 AM | marketbeat.comNovem Group Invests $1.20 Million in Johnson & Johnson (NYSE:JNJ)May 22 at 8:01 AM | marketbeat.comBRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Grows Holdings in Johnson & Johnson (NYSE:JNJ)May 22 at 7:44 AM | marketbeat.comCss LLC Il Has $1.83 Million Stake in Johnson & Johnson (NYSE:JNJ)May 22 at 7:28 AM | marketbeat.comAmes National Corp Buys New Position in Johnson & Johnson (NYSE:JNJ)May 22 at 7:08 AM | marketbeat.comiSAM Funds UK Ltd Has $316,000 Stock Holdings in Johnson & Johnson (NYSE:JNJ)May 22 at 6:07 AM | marketbeat.comTwo Sigma Advisers LP Buys 61,493 Shares of Johnson & Johnson (NYSE:JNJ)May 22 at 5:56 AM | marketbeat.comJohnson & Johnson MedTech launches ultrasound catheter for imaging in cardiac ablation proceduresMay 22 at 1:00 AM | massdevice.comJohnson & Johnson's (NYSE:JNJ) Shareholders Will Receive A Bigger Dividend Than Last YearMay 22 at 1:00 AM | uk.finance.yahoo.comJohnson & Johnson (NYSE:JNJ) FDA Panel Supports DARZALEX FASPRO®? for High-Risk Multiple MyelomaMay 22 at 1:00 AM | finance.yahoo.comJohnson & Johnson (NYSE:JNJ) Trading Up 0.5% - Should You Buy?May 21 at 3:09 PM | marketbeat.comInvestors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to KnowMay 21 at 10:05 AM | zacks.comBIP Alliance LLC Makes New $368,000 Investment in Johnson & Johnson (NYSE:JNJ)May 21 at 8:12 AM | marketbeat.comJohnson & Johnson (NYSE:JNJ) Shares Purchased by White Knight Strategic Wealth Advisors LLCMay 21 at 8:12 AM | marketbeat.comMpwm Advisory Solutions LLC Takes Position in Johnson & Johnson (NYSE:JNJ)May 21 at 8:01 AM | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Stock Position in Johnson & Johnson (NYSE:JNJ)May 21 at 7:18 AM | marketbeat.comUSS Investment Management Ltd Sells 5,008 Shares of Johnson & Johnson (NYSE:JNJ)May 21 at 7:06 AM | marketbeat.comVoloridge Investment Management LLC Takes Position in Johnson & Johnson (NYSE:JNJ)May 21 at 6:53 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongIf You Wanted To Buy AbbVie and Didn’t, There’s Still Time To BuyBy Thomas Hughes | April 25, 2025View If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.By Leo Miller | April 28, 2025View 3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any MarketBy Chris Markoch | May 22, 2025View 3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any MarketJNJ and ABBV Company DescriptionsAbbVie NYSE:ABBV$183.31 +1.51 (+0.83%) As of 03:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Johnson & Johnson NYSE:JNJ$153.28 +0.10 (+0.06%) As of 03:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? These 4 Top Investors Bought Over 6 Million Broadcom Shares in Q1 Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith? Microsoft Could Rally as EU Antitrust Case Nears Resolution Canada Goose Soars 30%—Is This Rally Built to Last? Archer Rebuts Short Seller, Points to Strong Q1 & Global Momentum 5 Reasons You Will Be Glad You Bought Target in 2025 Moderna Stock Looks Ripe for a Short Squeeze Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
